AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13 nov. 2024 16h05 HE
|
AEON Biopharma
– Held biosimilar advisory meeting with FDA in Q3 2024, and aligned on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX®...
AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting
30 sept. 2024 08h00 HE
|
AEON Biopharma
– Company is aligned with the FDA on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference...
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
19 août 2024 16h05 HE
|
AEON Biopharma
IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin...
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
12 août 2024 16h05 HE
|
AEON Biopharma
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – – Scheduled to hold a biosimilar initial...
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
09 juil. 2024 08h00 HE
|
AEON Biopharma
– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 – IRVINE, Calif.,...
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan
29 mai 2024 08h00 HE
|
AEON Biopharma
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum...
AEON Biopharma Reports First Quarter 2024 Financial Results
14 mai 2024 16h05 HE
|
AEON Biopharma
– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints – – Evaluating next-steps across the Company’s...
AEON Biopharma Provides Update on Development Pipeline
09 mai 2024 08h00 HE
|
AEON Biopharma
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum...
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
03 mai 2024 07h00 HE
|
AEON Biopharma
IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum...
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
30 mars 2024 22h53 HE
|
AEON Biopharma
IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please note that in the first...